What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Heart failure (n=43316). Intervention: Hyponatremia vs. Non-hyponatremia. Primary outcome: All-cause mortality (HR 1.94, 95% CI 1.78-2.12).

December 22, 2023Open Access

Association between hyponatremia and adverse clinical outcomes of heart failure: current evidence based on a systematic review and meta-analysis

Key Result

Hyponatremia significantly increased the likelihood of all-cause mortality (HR 1.94) compared to non-hyponatremia in patients with heart failure.

Study Design

Type

Meta-Analysis (n=43,316)

Structured PICO

Does hyponatremia increase the risk of mortality in patients with heart failure?

Population

43,316 patients with heart failure pooled from 25 observational studies

Intervention

Hyponatremia (exposure)

Outcome

All-cause mortalityhard clinical

Hyponatremia is associated with a nearly two-fold increased risk of all-cause mortality in patients with heart failure, highlighting the prognostic importance of serum sodium levels.

Main Result

Effect estimate: HR 1.94 (95% CI 1.78-2.12)

Limitations

Notable degree of heterogeneity among the included studies
All incorporated articles were retrospective in design, potentially introducing unrecorded variables
Severity and classification of the enrolled HF patients varied
Frequency and timing of serum sodium measurements were inconsistent across studies
Duration of follow-up was inconsistent

Abstract

Background: Heart failure (HF) is a global health challenge. The perturbations in fluid and electrolyte equilibrium, particularly the compromised sodium balance associated with HF lead to high mortality rates. Hence, elucidating the correlation between serum sodium levels and the prognosis of HF is of paramount importance. This study aimed to conduct a comprehensive meta-analysis to thoroughly investigate the interplay between hyponatremia and the prognostic outlook of individuals with HF. Methods: A comprehensive search of bibliographic databases including PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted to identify relevant observational studies examining the association between hyponatremia and prognosis of HF. Data extraction, synthesis, and assessment of risk of bias were conducted. Meta-analytic methods, sensitivity analyses, and heterogeneity test were employed as appropriate to synthesize the data. Results: A total of 43,316 patients with HF were included spanning 25 selected studies. The pooled data revealed a notable association between hyponatremia and elevated risks across short and long-term mortality of HF. Specifically, hyponatremia was found to significantly increase the likelihood of all-cause mortality (Hazard ratio HR = 1.94, 95% confidence interval CI: 1.78-2.12); 1-year mortality (HR = 1.67, 95%CI: 1.46-1.90); 30-day mortality (HR = 2.03, 95%CI: 1.73-2.25); cardiac mortality (HR = 2.11, 95%CI: 1.81-2.46); and in-hospital mortality (HR = 1.64, 95%CI: 1.15-2.34). Conclusion: Our meta-analysis emphasizes the significant impact of hyponatremia on mortality in the HF patient population, highlighting the critical importance of maintaining stable serum sodium levels in HF management.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper